INTRODUCTION
Tachoflomb" is a product developed by Nycomed Arzneimittel, Germany, and is made of biological materials only, consisting of a sponge-like sheet of equine collagen coated on one side with human fibrinogen and bovine thrombin. The product is packaged in a ready-to-use format and can be stored under refrigeration at 4°C. When removed from its storage container it can be applied immediately to the surgical area requiring haemostasis.
Care must be taken to apply the fibrinogen/thrombin-coated side directly onto the target, traumatized tissues. The sheet, which provides a physical barrier, requires moistening with physiological saline to activate the reaction of the biological adhesives. In the presence of calcium ions in the physiological saline, the fibrinogen/thrombin adhesive complex polymerizes to form fibrin, thus creating an impermeable, insoluble barrier at the site of application that controls leakage.' The saline also softens the sheet to make it pliable and adhere to uneven surfaces.
At present, Tachof.omb" is used widely in thoracic and abdominal surgery to cover exposed surfaces following excision, and has been reported to be highly effective in controlling leakage from such areas." It has also been shown to successfully control oozing haemorrhage and to occlude dead spaces. The fibrin barrier is eventually removed by phagocytic activity of macrophages and repair cells.'
In this study, we investigated the use of TachoComb" in gynaecological/obstetric patients who required haemostasis for treatment of oozing haemorrhage. We evaluated the formation of post-surgical adhesions and the detection of persistent Tachoflomb" by second-look laparoscopy or laparotomy.
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MATERIALS AND METHODS
APPLICATION PROCEDURE
Tachotjomb" was used in patients treated at our clinic between October 1993 and April 1994. Patients had previously responded poorly to ligation, electrocoagulation and/or gauze compress for the control of oozing haemorrhage from pelvic surgical sites. Before application of Tachof.omb", blood and debris were removed from the area that underwent adhesiolysis and other areas showing evidence of oozing haemorrhage. A section of Tachoflomb", sufficient to cover the target area, was applied with the fibrinogen/thrombin-coated side in direct contact with the area requiring treatment. The collagen sheet was then moistened with physiological saline to activate the fibrinogen/thrombin complex of the coated side, and the entire surface of the sheet was fixed in position by applying gentle pressure for 3 -5 min ( Fig. 1 ).
POST-SURGICAL EVALUATION
The formation of post-surgical adhesions and the detection of macroscopically persistent Tachof.omb" was evaluated at one time point in each patient by second-look laparoscopy or, if evaluated during caesarean section, by laparotomy.
RESULTS
SURGICAL PROCEDURES REQUIRING HAEMOSTASIS
Sixteen women were evaluated (age, mean ± SD, 35.9 ± 6.8 years; range 25 -56 years). Clinical conditions that required 'Iachof.omb'" were: myoma, 12/16 (75%); cervical cancer, 1/16 (6.25%); endometrial cancer, 1/16 (6.25%); endometriosis, 1/16 (6.25%); and pelvic adhesive disease, 1/16 (6.25%). Surgical procedures for the clinical conditions were 10 myomectomies (62.5%). two radical hysterectomies (12.5%). two simple hysterectomies (12.5%). one oviductal reconstruction (6.25%) and one partial resection of the ovary due to cystic degeneration (6.25%). Tachoflomb" was most frequently applied to the uterine serosa and adjacent areas.
EFFICACY OF HAEMOSTASIS
Complete haemostasis of the oozing site was found in 14 cases (87.5%). and incomplete but adequate haemostasis in the remaining two cases (12.5%). Using second-look laparoscopy. one of the three women evaluated at 3 months after surgery showed slight macroscopic evidence of persisting Tachoflomb", whereas the other two women examined at 3 months showed no evidence of a persistent barrier (Fig. 2 ). In the one patient evaluated at 7 months by secondlook laparoscopy. and in the three patients observed by laparotomy during Caesarean section performed at 13 months. 3 years and 4 years. respectively. subsequent to initial surgery. no macroscopic evidence of persistent Tachoflomb" was observed. In addition. there was no evidence of de novo adhesion formation at the site of application in any patient.
DISCUSSION
We previously reported the development of a biological adhesive based on rabbit fibrinogen and thrombin." - 7 We also reported the use of this adhesive in autotransplants of the peritoneum to cover areas denuded during adhesiclysis.l-" - 13 Fibrin adhesive. in a haemostatic solution. is H Osada, H Tanaka, TK Fujii et aI.
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FIGURE 2
Site of TachoComb e application 3 months after initial surgery, observed with secondlook laparoscopy.
presently commercially available as Tisseel'" and Beriplast", TachuComb" is a fibrin adhesive coated onto a collagen sheet that provides haemostatic as well as physical barrier properties. Further. as this product is packaged as a ready-to-use product that can be stored under refrigeration, and therefore near a surgical operation area. no preparation of materials prior to use is necessary. The mechanisms involved in the instigation of adhesion formation am not yet understood completely: however, adhesion formation dOfJS frequently occur in areas of peritoneal dfJffJcts. 14 
Other caUSfJS of
Tisseel" is the wgisl"wd trade name of II11111UI10 AG. Austria: Beriplast" is the mgisll'rnd Iradn name of Behringwerkn AG, Corrnanv: Xoran" is tho rngisturod trade name of Shionogi Pharmaceuticals. lapan.
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adhesion formation include tissue hypoxia. foreign bodies [e.g. sutures. sponges). infections. dehydration and physical trauma. I:; One week after myomectomy. traditional adhesion prevention. including nylon sutures. adequate lavage. instillation of liquid barriers such as Xeran" (32'}{, dextran 70) resulted in > 70'}"o adhesion formation at the site of the myomectomy. Of these adhesions. 20% were extensive in area and so firm that they could not be lysed easily.
Another complication may he adhesion of the oviductal structures. which may result in infertility. The extent of surgical procedures and the individual response of patients undergoing surgery results in a wide range of reactions; however, it can be said that postsurgical adhesion formation is a natural event in the repair of surgically handled or H Osada, H Tanaka, TK Fujii et al.
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traumatized tissues." In women of childbearing age, the manipulation of pelvic structures that leads to adhesions may also be a cause of infertility, thus recent anti-adhesion products such as oxidized regenerated cellulose (Interceed®)l7,18 and hyaluronic acidcarboxymethylcellulose film (Seprafilm®p9,2o have become available, but their effect is less than optimal. Therefore, the lack of adhesion formation, established either using second-look laparoscopy performed 3 -7 months after surgery or using laparotomy in the women who underwent Caesarean section at 13 months -4 years after surgery, offers hope that effective adhesion suppression is possible. In gynaecological surgery on women of childbearing age, Tachof.ornb" used as an adhesion preventative may thus be an effective method of preventing adhesion-induced infertility.
The speed of degradation and absorption of Tachof.omb" may be dependent on the site of application and the quantity used; however, it is removed biologically in a relatively short time by the action of plasmin and other defence mechanisms. In animal studies, collagen sheet adhesive is removed from dog liver, dog brain and rabbit kidney in about 3 months." When applied at a uterine cervical biopsy, no evidence of residual collagen adhesive was detected 6 weeks after biopsy." In rats, TachoComb'" was not detected at the site of application 16 -20 weeks after biopsy, Tachoflomb'" consists of a sponge-like sheet of equine collagen, coated on one side with fibrinogen and thrombin that are activated after the sheet is properly placed to control oozing from traumatized tissues. Using laparoscopy and laparotomy observation methods, we have shown the sheet to be effective in controlling haemorrhage and suppressing post-surgical adhesion. Tachof'omb" was degraded naturally, and there was no evidence of the sheet at observation in nearly all patients examined. In women requiring pelvic surgery, Tachof.omb" may, therefore, be an effective product to prevent post-surgical adhesion and to prevent loss of fertility.
Interceed" is the registered trade name of Johnson & Johnson Medical Inc" USA; Seprafilrn" is the registered trade name of Genzyme Corp" USA,
